BIBLIOGRAFÍA

1. Fischer G, Wittman-Liebold K, Lang K, Kiefhaber T, Schmid FX. Cyclophilin and peptidyl-propyl cis-trans isomerase are probably identical Proteins. Nature 1989; 337: 476-8.

2. Jorgensen KA, Koefoed-Nielsen PE3. Calcineurin Phosphastase Activity and Immunosuppression. A review on the role of Calcineurin Phosphatase Activity and the Immunosuppresive effect of Ciclosporin A and Tacrolimus. Scand J lmmunol 2003; 57:93-98
   
   

3. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of ciclophilin, cyclosporin A and FKBP-FK506. Cell 1991, 66: 807-15
   
   

4. Shi Y, Frankel A, radmayi Lg, Penn LZ, Miller RG, Mills GB. Rapamycin enhances apoptosis and increase sensitivity to cisplatin in vitro. Cancer Res 1995; 55: 1982-8
   
   

5. Noguera A, Masso J, Soy D, Codina C, Ribas J. Sirolimus: una alternativa en el tratamiento inmunosupresor. Farmacia Hospitalaria 2002,26: 96-105.
   
   

6. Nghiem P Pearson G, Langley RG. Tacrolimus and pimecrolimus: From clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis Jam Acad 2002; 46:228-41.
   
   

7. Ruzicka T, Assman T, Bernhard H. Tacrolimus: The drug for the turn of the millennium. Arch Dermatol 1999: 135: 574-580.
   
   

8. Bornhovd E, Burgdorf W, Wollenberg A. Macrolatam immunomodulators for topical treatment of inflamatory skin disease. J Am Acad Dermatol 200 1; 45:736-43
   
   

9. Lepe et al. Childhood Vitiligo and Tacrolimus. Arch Dermatol
   2003; 139: 651-653.
   
   

10. Kirby 0, Griffithis M. Novel immune based therapies for psoriasis. Br J Dermatol 2002; 146: 546-551.
    
    

11. Karampers N, Poulsen JV Hojskov C. Comparasion of the pharmacokinetics of Tacrolimus and cyclosporine at equivalent molecular doses. Transplant Proc 2003; 35:1314-8
    
    

12. Choi C, Nghiem P Tacrolimus Ointment in the Treatment of Chronic Cutaneous Graft vs Host Disesase : A case series of 18 patients. Arch Dermatol 200 1; 137:1202-06.